Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer
Abstract Objective Cemiplimab, a novel PD-1 inhibitor, exhibits significant antitumor activity against advanced non-small cell lung cancer (NSCLC). However, the cost-effectiveness of this drug for the treatment remains unclear. This study aimed to assess the cost-effectiveness of cemiplimab plus che...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-11992-6 |
| _version_ | 1797274320297263104 |
|---|---|
| author | Yitian Lang Yan Lin Meng Deng Xiaoyan Liu |
| author_facet | Yitian Lang Yan Lin Meng Deng Xiaoyan Liu |
| author_sort | Yitian Lang |
| collection | DOAJ |
| description | Abstract Objective Cemiplimab, a novel PD-1 inhibitor, exhibits significant antitumor activity against advanced non-small cell lung cancer (NSCLC). However, the cost-effectiveness of this drug for the treatment remains unclear. This study aimed to assess the cost-effectiveness of cemiplimab plus chemotherapy compared to chemotherapy for the treatment of advanced NSCLC, from the perspective of the United States payer. Methods A partitioned survival approach was developed to project the disease progression of NSCLC. Overall survival (OS) and progression-free survival (PFS) data were obtained from the EMPOWER lung 3 trial and extrapolated to estimate long-term survival outcomes. Direct medical costs and utility data were collected. The primary outcome measure, the incremental cost-utility ratio (ICUR), was used to evaluate the cost-effectiveness of cemiplimab plus chemotherapy regimen. One-way sensitivity analyses (OWSA) and probabilistic sensitivity analyses (PSA) were conducted to assess the robustness of the results. Results In the base-case analysis, the ICUR for cemiplimab plus chemotherapy versus chemotherapy alone was estimated to be $395,593.8 per quality-adjusted life year (QALY). OWSA revealed that the results were sensitive to Hazard ratio value, utility of PFS, and cost of cemiplimab. PSA demonstrated that cemiplimab plus chemotherapy exhibited 0% probability of cost-effectiveness.In hypothetical scenario analysis, the ICUR of two regimens was $188.803.3/QALY. OWSA revealed that the results were sensitive to the discount rate, utility, and cost of cemiplimab. PSA indicated that cemiplimab plus chemotherapy achieved at least an 11.5% probability of cost-effectiveness. Conclusion Our cost-effectiveness analysis suggests that, at its current price, cemiplimab plus chemotherapy regimen is unlikely to be a cost-effective option compared with chemotherapy alone for advanced NSCLC patients, based on a threshold of $150,000 per QALY, from the perspective of the US payer. |
| first_indexed | 2024-03-07T14:56:43Z |
| format | Article |
| id | doaj.art-ac5b58440b4040d89c58bffe0d9288b3 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-07T14:56:43Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-ac5b58440b4040d89c58bffe0d9288b32024-03-05T19:24:13ZengBMCBMC Cancer1471-24072024-02-0124111110.1186/s12885-024-11992-6Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancerYitian Lang0Yan Lin1Meng Deng2Xiaoyan Liu3Department of Pharmacy, Huangpu Branch, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Pharmacy, Huangpu Branch, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Pharmacy, Huangpu Branch, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Pharmacy, Huangpu Branch, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of MedicineAbstract Objective Cemiplimab, a novel PD-1 inhibitor, exhibits significant antitumor activity against advanced non-small cell lung cancer (NSCLC). However, the cost-effectiveness of this drug for the treatment remains unclear. This study aimed to assess the cost-effectiveness of cemiplimab plus chemotherapy compared to chemotherapy for the treatment of advanced NSCLC, from the perspective of the United States payer. Methods A partitioned survival approach was developed to project the disease progression of NSCLC. Overall survival (OS) and progression-free survival (PFS) data were obtained from the EMPOWER lung 3 trial and extrapolated to estimate long-term survival outcomes. Direct medical costs and utility data were collected. The primary outcome measure, the incremental cost-utility ratio (ICUR), was used to evaluate the cost-effectiveness of cemiplimab plus chemotherapy regimen. One-way sensitivity analyses (OWSA) and probabilistic sensitivity analyses (PSA) were conducted to assess the robustness of the results. Results In the base-case analysis, the ICUR for cemiplimab plus chemotherapy versus chemotherapy alone was estimated to be $395,593.8 per quality-adjusted life year (QALY). OWSA revealed that the results were sensitive to Hazard ratio value, utility of PFS, and cost of cemiplimab. PSA demonstrated that cemiplimab plus chemotherapy exhibited 0% probability of cost-effectiveness.In hypothetical scenario analysis, the ICUR of two regimens was $188.803.3/QALY. OWSA revealed that the results were sensitive to the discount rate, utility, and cost of cemiplimab. PSA indicated that cemiplimab plus chemotherapy achieved at least an 11.5% probability of cost-effectiveness. Conclusion Our cost-effectiveness analysis suggests that, at its current price, cemiplimab plus chemotherapy regimen is unlikely to be a cost-effective option compared with chemotherapy alone for advanced NSCLC patients, based on a threshold of $150,000 per QALY, from the perspective of the US payer.https://doi.org/10.1186/s12885-024-11992-6Cost-effectivenessNon-small cell lung cancerCemiplimab plus chemotherapyPartitioned survival approach |
| spellingShingle | Yitian Lang Yan Lin Meng Deng Xiaoyan Liu Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer BMC Cancer Cost-effectiveness Non-small cell lung cancer Cemiplimab plus chemotherapy Partitioned survival approach |
| title | Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer |
| title_full | Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer |
| title_fullStr | Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer |
| title_full_unstemmed | Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer |
| title_short | Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer |
| title_sort | economic evaluation of cemiplimab plus chemotherapy regimen for advanced non small cell lung cancer |
| topic | Cost-effectiveness Non-small cell lung cancer Cemiplimab plus chemotherapy Partitioned survival approach |
| url | https://doi.org/10.1186/s12885-024-11992-6 |
| work_keys_str_mv | AT yitianlang economicevaluationofcemiplimabpluschemotherapyregimenforadvancednonsmallcelllungcancer AT yanlin economicevaluationofcemiplimabpluschemotherapyregimenforadvancednonsmallcelllungcancer AT mengdeng economicevaluationofcemiplimabpluschemotherapyregimenforadvancednonsmallcelllungcancer AT xiaoyanliu economicevaluationofcemiplimabpluschemotherapyregimenforadvancednonsmallcelllungcancer |